Peer Review History
| Original SubmissionMay 31, 2025 |
|---|
|
Dear Dr. Sriyani, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 22 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Nicholas Aderinto Oluwaseyi Academic Editor PLOS ONE Journal Requirements: 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please describe in your methods section how capacity to provide consent was determined for the participants in this study. Please also state whether your ethics committee or IRB approved this consent procedure. If you did not assess capacity to consent please briefly outline why this was not necessary in this case. 3. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 4. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.] Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition). For example, authors should submit the following data: - The values behind the means, standard deviations and other measures reported; - The values used to build graphs; - The points extracted from images for analysis. Authors do not need to submit their entire data set if only a portion of the data was used in the reported study. If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: No Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: 1) Although the authors indicate that the study site admits patients from allover the country, admissions are basically from the Western province and this limits the applicability of data to other regions of the country. The sample is highly selective. 2) The described physical and mental impacts cannot be attribute to methamphetamine, as most of them were on other psychoactive drugs or agents. 3) The physical effects described are very non specific. e.g weight loss (subjective or objective), cough (was it based on the duration or severity), anorexia Reviewer #2: Comments to the Editor Dear Editor, Thank you for the opportunity to review this manuscript. The study addresses an important and underexplored topic: the patterns, severity, and impacts of Methamphetamine addiction among adults receiving treatment in Sri Lanka. While it provides useful local evidence, the manuscript would benefit from substantial revisions to strengthen its clarity, coherence, and scholarly contribution. Please find my detailed comments below. Introduction • The opening sentence is acceptable but could be made more impactful by highlighting why this stimulant poses a particular threat in low- and middle-income country contexts, where treatment and harm-reduction services are limited. • The transition from global to Asian data is abrupt. Adding a bridging sentence would improve the flow (e.g., “This global trend is reflected in Asia, where…”). • Ensure numerical comparisons are clear and impactful; for example, show percentage increases when comparing 2022 to 2023 arrest data. • Some phrasings are redundant (e.g., “widespread effects that are multifaceted and interrelated…” could be simplified). • When citing multiple sources, consider combining them for readability. • The rationale for the study could be clearer: specify how this study will explore local motivations in depth. • The research gap paragraph should be more assertive: e.g., “Despite rising prevalence, there is a critical lack of detailed, community-based research…” • Split the aim statement into clear, bullet-pointed objectives for easy reading. • Minor grammatical edits: use “aged 12 or older” instead of “age 12 or older”; merge repetitive sentences for conciseness. Methods • Important details on sampling and recruitment procedures are missing. How were participants identified and selected? • Use consistent past tense for the study design description. Avoid repetition when describing the setting. • Clarify how DSM-5 diagnoses were confirmed — by whom and based on what process? • Explain how withdrawal symptoms were identified and excluded during recruitment. • Confirm that the source for the DSM-5 criteria is cited correctly. • For the pattern-of-use questions, indicate whether these items were validated or developed by the authors. If author-developed, how were they pre-tested and improved? • You mention open-ended questions but do not explain how responses were coded and analyzed — this should be described briefly. • Good to note the pre-test and Cronbach’s alpha; specify how feedback from the pre-test informed final revisions. • In data collection, mention how many interviewers were involved and whether inter-rater reliability was checked. • In data analysis, clarify that only descriptive statistics were planned if no inferential analysis was done; explain how missing data were handled. • Ensure consistent tense and phrasing: e.g., “due to the population represents…” should be “because the population represents…” it is not clear why data was only analyzed descriptively. Rigorous data analysis would benefit the study. what confounding factors were detected and how were they controlled? Results • It is unclear why “Muslim” is classified as an ethnicity rather than a religious group — please clarify or adjust the categorization. • The education level categories (primary, secondary, tertiary, higher, vocational) are not clearly defined — consider aligning with standard classifications. • Use consistent past tense when reporting results. • Ensure small percentages are formatted consistently. • Tables are generally well-structured, but check for decimal alignment. Clarify in the polydrug use table that multiple responses were possible. • Heatmaps should be correctly labeled in the text as “Figure 1A,” “Figure 1B,” etc., and figures should be cross-referenced appropriately. • When reporting severity and patterns, add a line to interpret what the distribution implies. • Small details: use “Separated” instead of “Separate” for social status. Clarify overlap between similar items such as “isolation from family” and “lack of family closeness.” • Briefly interpret the significance of polydrug use and social impacts to guide the reader’s understanding. Discussion • The Discussion should more clearly compare the study’s findings with previous research, highlighting reasons for similarities and differences. • Some points are repeated unnecessarily (e.g., male predominance, cultural stigma, physical impacts). Combine these for conciseness. • Expand on the implications of polydrug use for treatment planning, withdrawal management, and relapse prevention in local contexts. • For physical impacts, tie findings to specific clinical consequences (e.g., the need for nutritional or dental interventions). • When citing other studies, integrate citations meaningfully: show how your results align with or differ from theirs. • Limitations are acknowledged but could be stronger: note the reliance on self-reported data, the potential for under- or over-reporting, and the lack of generalizability due to the single-site setting. • Highlight the strengths of the study (e.g., high response rate, comprehensive coverage of impacts). • Offer recommendations for future research, such as using mixed methods or longitudinal designs. Conclusion • The conclusion should be more precise and actionable. Avoid generic phrases like “sheds light”; instead, state what this study adds empirically and how it informs policy and practice. • Summarize clear, evidence-based recommendations: e.g., the need for peer-led prevention, youth-focused outreach, integrated mental health services, and stricter control of Methamphetamine supply chains. Overall Recommendation This study addresses an important gap and has merit. However, significant revisions are required to strengthen the introduction, clarify methods, ensure consistency in reporting, expand the discussion, and refine the conclusion. I therefore recommend major revision before the manuscript can be considered for publication. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Dr Ngozika Esther Ezinne ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Dear Dr. Sriyani, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Oct 12 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Nicholas Aderinto Oluwaseyi Academic Editor PLOS ONE Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Reviewer #2: [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: (No Response) ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: No ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes ********** Reviewer #2: Comments to the Editor Dear Editor, Thank you for the opportunity to review this manuscript. The authors address an urgent and underexplored public health issue—methamphetamine addiction in Sri Lanka—using a descriptive cross-sectional design. The manuscript makes a valuable contribution by presenting primary clinical data from the National Institute of Mental Health, the country’s leading treatment center. The large sample size (n=427), high response rate, and comprehensive exploration of perceived physical, psychological, and social impacts are commendable. However, while the manuscript highlights an important issue, several methodological and interpretive limitations reduce its scientific rigor. Minor revisions are required to strengthen the study before it is suitable for publication. Comments How were open-ended responses systematically coded (beyond thematic grouping)? Was the DSM-5 checklist interviewer-administered or self-reported? The reported Cronbach’s alpha (0.89) applies only to severity items, not the entire instrument. Reliability and validity of other sections remain unclear. Addiction severity is classified according to DSM-5 symptom count, but it is unclear whether clinicians verified responses or whether lay interviewers applied criteria. Misclassification risk should be acknowledged. The analysis is largely descriptive. Inferential or multivariate analyses (e.g., associations between demographics and severity) could provide greater depth. No adjustment for multiple testing is reported, despite numerous outcome measures. This raises concern about inflated type I error. The manuscript often implies causality (e.g., “methamphetamine causes family separation”) despite the cross-sectional design. The authors should temper causal language. The very high rate of polydrug use (87%) is striking but insufficiently discussed. How does this affect interpretation of methamphetamine-specific impacts? Many “perceived impacts” may be attributable to multiple substances. Strengths and limitations should be presented more systematically. Currently, limitations are underplayed. Several grammatical and typographical errors reduce clarity (e.g., “boos energy” → “boost energy”; “ticket the box” → “ticked the box”). Figures/heatmaps are visually appealing but need clearer legends and consistency in labeling. Conclusions should align more closely with the descriptive nature of the study and avoid policy overreach without stronger evidence. Recommendation This manuscript provides much-needed data on methamphetamine use in Sri Lanka. However, methodological weaknesses (sampling, measurement, analysis) and interpretive overstatements must be addressed to improve validity and impact. With substantial revision, the paper has the potential to make a meaningful contribution to the literature on substance use in South Asia. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: Yes: Ngozika Esther Ezinne ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org |
| Revision 2 |
|
Dear Dr. Sriyani, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Dec 17 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Nicholas Aderinto Oluwaseyi Academic Editor PLOS ONE Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: No ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes ********** Reviewer #2: Authors revision of the manuscript has helped to improve the quality but I still have few comments. 1. Study design & claims • The paper repeatedly infers or implies determinants of severity from cross-sectional and largely descriptive/bivariate data. Causality cannot be inferred. Please re-frame throughout as associations among treated in-patients/outpatients at NIMH. 2. Target condition & measurement • Diagnostic ascertainment is described as “DSM-5 criteria confirmed by consultant psychiatrists or psychiatric medical officers using structured clinical interviews and medical records” but the specific instrument (e.g., SCID-5, MINI) is not named. Please specify the instrument(s), training, version, languages, and whether inter-rater calibration was conducted. • Severity scoring: DSM-5 SUD severity (2–3 mild, 4–5 moderate, 6–11 severe) is a categorical rubric for diagnosis, not a psychometric scale. Reporting Cronbach’s α=0.89 on DSM-5 symptom items is not appropriate (the criteria are formative/diagnostic, not reflective indicators). Remove α for DSM-5 items; if you retain reliability analyses, do so only for any new multi-item scales designed to measure a single latent construct. • Perceived impacts: Open-ended responses were coded thematically, but the codebook, exemplar quotes, intercoder reliability for each domain, and denominator handling (multiple responses permitted) are not reported. Provide: (i) codebook in Supplement, (ii) examples per theme, (iii) how you calculated percentages (per total N vs. per respondents endorsing any item), and (iv) κ per key code if feasible. 3. Polydrug use as a confounder • With 87% reporting polydrug use, nearly all “impacts” and “associations with severity” are plausibly confounded. Current analyses do not adjust for concurrent alcohol, cannabis, heroin, or tobacco. You should: o Present stratified descriptives by polydrug vs. methamphetamine-only. o Include polydrug use indicators in multivariable models (see below) or conduct sensitivity analyses excluding heavy polydrug users. 4. Statistical analysis—move beyond bivariate tests • The table “Associated factors for Methamphetamine use severity” is based on χ²/Fisher’s tests only. To support statements such as “severity was associated with…”, perform multivariable modeling: o Primary: Ordinal logistic regression (proportional odds) with severity (mild/moderate/severe) as outcome; test proportional-odds assumption (e.g., Brant test). If violated, use multinomial logistic regression. o Covariates: age, sex, education, income, living area, living arrangement, age of onset, frequency, route, accessibility, and polydrug indicators. Consider province fixed effects. o Report adjusted odds ratios with 95% CIs and model fit (pseudo-R², likelihood ratio tests). o Provide effect sizes for bivariate tests (e.g., Cramér’s V) even if you keep the table. • Multiple testing: You state no correction was applied. Either prespecify a primary model and outcomes to mitigate multiplicity, or apply FDR/Bonferroni for the large number of comparisons, and explicitly mark adjusted p-values. • Some internal inconsistencies appear (see Minor comments). Please audit all frequencies and denominators. 6. Figures & tables—clarity and reproducibility • Heatmaps are visually engaging but readers need numerical tables (counts and percentages) in the main text or Supplement for each impact domain. State clearly that items were multiple-response and give the exact denominator used for each percent. • Table footnotes should define all categories (e.g., “Urban/Semi-urban/Rural” operationalization; “Isolation from family” vs. “lack of family closeness”). Ensure consistent capitalization (use “methamphetamine” not capitalized unless sentence-initial). • Standardize decimal precision (e.g., one decimal place for percentages) and align counts (n, %). 7. Interpretation & positioning • Some narrative sections over-generalize to the population of Sri Lanka or suggest policy effects beyond the sampling frame. Re-anchor claims to treatment-seeking adults at NIMH. • Where your findings diverge from international literature (e.g., higher income and urban residence associated with greater severity), propose contextual hypotheses and acknowledge alternative explanations (clinic catchment, enforcement patterns, access/affordability, reporting bias). 8. Ethics & participant capacity • You excluded “acute intoxication/withdrawal” and “cognitive impairment,” relying on clinicians’ judgment. State how capacity to consent was assessed (beyond “coherent, alert, oriented”) and whether interpreters were used for non-Sinhala/Tamil speakers. Confirm whether participation affected care in any way (it should not). Consider adding a distress protocol for participants reporting suicidal ideation. 9. Language & stigma • Use “methamphetamine” (lowercase) consistently; reserve “ICE” to a footnote and avoid slang in academic prose. Minor comments (presentation & housekeeping) Title & keywords • Title is long and partially duplicated; consider: “Methamphetamine use disorder, perceived impacts, and associated factors among adults receiving care at Sri Lanka’s National Institute of Mental Health: an analytical cross-sectional study.” • Add keywords reflecting methods (e.g., “polydrug use,” “ordinal logistic regression,” “South Asia”). Abstract • include design, setting, sample, main analysis (and specify that only bivariate tests were used if multivariable is not added), principal adjusted results (after you add models), • Methods—instrument details • Provide the full questionnaire (English + translated versions) as Supplementary File with source citations for borrowed items and the exact DSM-5 item prompts used. • Clarify how accessibility and frequency were operationalized and whether recall periods were specified. Results—consistency • In Table 1, present n (%) consistently for all rows. Some rows show only % in text and n in table headings. Verify “Living with whom—other” count (9) vs. severity table shows “other 0” in mild category row; check alignment. • A few typographical issues: stray commas/spaces, inconsistent hyphenation (semi-urban vs semi urban), and inconsistent province capitalization. Figures • Ensure figure captions define color scales, denominators, and that each heatmap is reproducible from the provided counts. References • Some duplicates (“World Drug Report 2020” listed twice as 1 and 3). Several references are not ideal primary sources for mechanistic claims (e.g., American Addiction Centers webpage). Replace with peer-reviewed or UNODC/WHO technical documents where possible. • Check numbering order vs. first citation order; ensure in-text numbers match. Suggested analytic upgrades (concrete) 1. Primary model: Ordinal logistic regression with severity (0=mild, 1=moderate, 2=severe). Predictors: age (continuous), sex, education, income (quintiles), living area, living arrangement, age of onset (categorical), frequency (ordinal), route (dummy variables), perceived accessibility (ordinal), polydrug indicators (alcohol, cannabis, heroin, tobacco, other), and province. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 3 |
|
Methamphetamine use disorder, perceived impacts, and associated factors among adults receiving care at Sri Lanka’s National Institute of Mental Health: An analytical cross-sectional study PONE-D-25-28029R3 Dear Dr. Sriyani, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Nicholas Aderinto Oluwaseyi Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes ********** Reviewer #2: I do not have any further comments as authors have responded to all my comments. The quality of the manuscript has now improved. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No ********** |
| Formally Accepted |
|
PONE-D-25-28029R3 PLOS One Dear Dr. Sriyani, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Nicholas Aderinto Oluwaseyi Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .